another 3.6 million are at an increased risk. In men over 64 years of age, 80% of hip fractures are attributed to osteoporosis, costing a national direct expenditure of $13.8 billion in 2000. Earliest diagnosis is through a bone density test, which could help in prevention of hip fractures and significant savings in health care costs. This study examines the various physician and patient factors, which influence the bone density test prescribing for osteoporosis in male ambulatory patients. METHODS: Patient factors such as age, race, geographical location and payment source, and Physician factors such as specialty and referral status were used to determine their influence on the number of bone density tests prescribed. Data from the National Ambulatory Medical Care Survey (NAMCS) 2002 were utilized. Male patients with principal diagnosis of osteoporosis (ICD-9-CM code 733.00) with age more than or equal to 50 years were analyzed using multiple linear and binomial logit regression models. RESULTS: The number of bone density tests performed were independent of patients’ geographic region ($R^2 = 0.111$). White patients were prescribed more bone density tests compared to other races ($R^2 = 0.436$). Patients above 75 years of age and patients with Federal source of payments were prescribed more bone density tests than other patients ($R^2 = 0.345$). Numbers of bone density tests were not influenced by whether the patient was referred ($R^2 = 0.027$). Family Practice physicians prescribed more bone density tests compared to other specialties ($R^2 = 0.326$). CONCLUSIONS: The numbers of bone density tests prescribed are significantly influenced by patients’ race, age and source of payments, and physician’s specialty. Bone density screening for men over 50 years of age appears to be an optimal approach to manage osteoporosis in men.

**POST-OSTEOPOROTIC FRACTURE DRUG TREATMENT FOR OSTEOPOROSIS IN NURSING HOME ELDERLY**

**Ye X**, Eberly LE, Harms SL, Garrard JM

**University of Minnesota, Minneapolis, MN, USA**

**OBJECTIVES:** A preexisting fracture is a very strong predictor of subsequent osteoporotic fractures, emphasizing the need to aggressively treat patients with existing osteoporotic fractures. The objectives of the study are to examine the prevalence of drug treatment and factors associated with drug treatment among elderly nursing home (NH) admissions with an indication of osteoporotic fracture. METHODS: The Minimum Data Set for Nursing Home Assessment and Care Screening (MDS) Version 2.0 and physicians’ medication orders from 1999 were utilized for this study. The outcome was the use of anti-osteoporotic drug therapy at NH admission. Independent variables included patient demographics, comorbidities, functional capabilities (activities of daily living or ADLs), and cognitive performance (MDS-COGS). Multivariate analysis was conducted using logistic regression with Generalized Estimating Equations (GEE) to adjust for clustering within NH facilities. RESULTS: A total of 2673 NH residents were identified with documentation of osteoporotic fracture within 180 days or affecting current care at admission; however, only 642 (24.02%) received anti- osteoporotic drug therapy at admission. Gender ($p < 0.0001$), age ($p = 0.0394$), and functional capabilities ($p = 0.0002$) were significantly associated with the use of anti-osteoporotic drug. Non-significant factors were region, race, education, comorbidity and cognition. Treatment was less likely for male residents (OR: 0.45; 95% CI, 0.33–0.62) and residents older than 85 (OR: 0.79; 95% CI, 0.67–0.97). Those who were independent in terms of ADLs were more likely to receive drug treatment (OR: 2.54; 95% CI, 1.27–5.07), compared to those who were fully dependent. CONCLUSIONS: While osteoporotic fracture is common among the NH elderly population, the majority remained untreated. Increasing age was inversely related to receipt of anti-osteoporotic drugs. Female elderly and those with fewer limitations in daily activities were more likely to receive drug therapy for osteoporosis.

**POS6 IMPACT OF AN OSTEOPOROSIS INTERVENTION PROGRAM OF PATIENTS WITH A FRACTURE HISTORY**

**Park J1, Ara SB2**

1Health Net Pharmaceutical Services, San Bernardino, CA, USA; 2Health Net Pharmaceutical Services, Woodland Hills, CA, USA

**OBJECTIVE:** To evaluate the impact of an osteoporosis therapy intervention program in a health plan setting. METHODS: A clinical team of pharmacists, obstetricians/gynecologists and endocrinologists designed and implemented an educational initiative for physicians and members. Medical and pharmacy claims data for female enrollees over the age of 40 were retrieved for the time period of July, 2002 through June, 2003. Criteria for targeted patients included a fracture history (defined by ICD-9 and CPT codes) and negative history of estrogen/progestin use over the 1-year period, and four-month negative history of osteoporosis therapy (alendronate, risedronate, calcitonin, raloxifene, or teriparatide). Physicians received a patient list, an educational tool for management of osteoporosis and coupons for a free first-month supply of a bisphosphonate. Targeted members received a 17-page handbook highlighting drug treatment, lifestyle modifications, and information regarding prescription drug discount programs. The impact of the intervention was analyzed using pharmacy claims data for eligible patients with pharmacy benefits. Primary outcome measure was defined as the percent of patients with a claim for an osteoporosis agent at three, six, and nine-months post-intervention. Additionally, a member survey was conducted six-months post-intervention to evaluate the member mailing. RESULTS: There were 1612 program participants. At three, six and nine-months respectively, 3.76% (32/852), 5.12% (40/781) and 5.97% (42/704) of eligible patients had a claim for an osteoporosis agent. A 23% survey response rate was achieved (364/1612). Survey results indicated 18% of responders were taking prescription osteoporosis medications at that time. Post-intervention, 19% of the responders made a doctor appointment, 15% attended the appointment, 17% received a prescription, 13% received medication samples, and 11% filled the prescription. CONCLUSION: Survey results indicate higher rate of medication use compared to claims database analysis, which does not capture medication sampling. Another mailing has been done to continue to improve osteoporosis care.

**POS7 VALIDATION STUDY OF THE OSTEOPOROSIS PATIENT SATISFACTION QUESTIONNAIRE (OPSAT-Q)**

**Flood E1, Beusterien K1, Baran R2, Shiklar R3, Cella D4**

1MEDTAP International, Bethesda, MD, USA; 2Roche Laboratories Inc, Nutley, NJ, USA; 3MEDTAP International, Seattle, WA, USA; 4Evanston Northwestern Healthcare, Evanston, IL, USA

**OBJECTIVE:** Several features of bisphosphonate therapy for osteoporosis may influence patient satisfaction, including dosage convenience. The objective of this study was to evaluate the psychometric characteristics of the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q), which assesses patient satisfaction with osteoporosis treatment. METHODS: Patient focus groups and cognitive debriefings informed the development of the 16-item OPSAT-Q, which contains four subscales: Convenience, Confidence with Daily Activities, Side Effects and Overall Satis-
PAIN

PPN1
REDUCING MORTALITY IN PATIENTS WITH SUBSTANCE ABUSE AND CHRONIC NON-MALIGNANT PAIN THROUGH A MULTIDISCIPLINARY OPIOID RENEWAL CLINIC
Sampson JM, Marsh B
VA Medical Center, Gainesville, FL, USA

OBJECTIVE: Is it safe to treat patients with opioids for chronic non-malignant pain who have histories of substance abuse or addiction? Mortality rates for substance abusers are three times the general population rate. There are few outcome studies in the medical literature. The Opioid Renewal Clinic follows patients closely with drug testing, laboratory monitoring, and provides group education with outside speakers. On site drug counseling is provided to those determined to be in need. A full range of consultation services are available. The disciplines that make up the clinic include Pharmacy, Nursing, Social Work, Internal and Addiction Medicine. Disease management guidelines are incorporated into the structure of the clinic.

METHODS: This was a retrospective age adjusted mortality study of 250 Primary Care consults over a two-year period to a multidisciplinary Opioid Renewal Clinic. The most common reason for consultation was the difficult to manage patient secondary to substance abuse. The renewal clinic maintains between 80 to 100 patients. Kaplan-Meier survival curves were performed for pain patients on opioids in Primary Care and the opioid renewal clinic. Key variables were evaluated by regression analysis.

RESULTS: There were six deaths in patients in Primary Care and two deaths in patients followed in the Renewal Clinic. The odds ratio of deaths in usual care to clinic is three, or three times the rate of the Renewal Clinic. Patients were between 40–60 years of age. Deaths due to known cancer, cardiac or liver disease were excluded. Cancer deaths were predominantly lung, and associated with tobacco use. CONCLUSIONS: A Multidisciplinary Opioid Renewal Clinic can reduce short term mortality in high risk patients. Further studies are recommended to assess long term mortality rates and secondary outcomes on cancer prevention, disease management, and control of depression.

PPN2
EVALUATION OF THE DIRECT COSTS OF PURE NEUROPATHIC PAIN MANAGEMENT IN FRANCE BEFORE A FIRST CONSULTATION IN A PAIN MANAGEMENT CENTER
Duru G1, Garassus P1, Lantéri-Minet M1, Lamarsalle L4, Von Raison F1, Solesse-de Gentre A5
1Université C. Bernard Lyon I, Villeurbanne, France; 2Clinique du Tonkin, Villeurbanne, France; 3Hôpital Pasteur, NICE, France; 4GYS Institut—IMS Health, Lyon, France; 5Pfizer; Paris cedex 14, France

OBJECTIVES: Pain management centers provide the most appropriate care for pure neuropathic pain. But before consulting such a center, patients often indulge in “medical nomadism”, thereby incurring substantial additional costs. This study aimed to describe the medical trajectory and to estimate the direct costs of a patient sample with pure neuropathic pain (i.e. with no nociceptive component) during the year before their first consultation in a pain management center. METHODS: Retrospective data collected by patient questionnaires were used for this cross-sectional study, in which ten pain management centers participated between January and April, 2004. A total of 116 patients who gave written consent and were able to answer the questionnaire were assessed. The economic outcomes were the total and refunded Direct Medical Consumption (DMC), including all costs directly related to the pathology: medical and para-medical consultations, drugs, other treatments (surgery, nerve stimulation, etc.), examinations, and hospitalizations. Costs were determined by medical fees, official drugs and examinations tariffs, and Diagnosis Related Groups (DRGs). A bootstrap technique was used to improve statistical strength.

RESULTS: The total and refunded average cost per patient ranges from 4630 € to 6830 € and from 3500 to 5690 €, depending on the hospitalization sector, private or public. The most costly items are “Hospitalizations” and “other treatments”, representing 31% and 24% respectively of the total cost in the private sector, and 46% and 23% in the public sector. The “drugs” item only represents 12% private and 8% in the public sector. CONCLUSION: This study, based mainly on recalled declarative data, may be subjectively biased. Nonetheless, the results give a plausible estimation of direct annual costs of neuropathic pain management in France before its appropriate management in a specialized center, a field where few data are available.

PPN3
SUMMARY OF HOSPITAL LOGISTICS ASSOCIATED WITH INTRAVENOUS PATIENT-CONTROLLED ANALGESIA (IV PCA) FOR ACUTE POSTOPERATIVE PAIN MANAGEMENT
Zhang M1, Anastassopoulos K2, Hutchison R3, Olson WH1, Goss TF1, Hewitt D1, Gargiulo K1, Siccardi M1, Mordin M2
1Ortho McNeil Pharmaceutical, Inc, Raritan, NJ, USA; 2Covance Health Economics and Outcomes Services Inc, Gaithersburg, MD, USA; 3Presbyterian Hospital, Dallas, TX, USA

OBJECTIVES: To characterize hospital IV PCA pump and analgesia acquisition, inventory, and logistics for acute postoperative pain management. METHODS: Data were collected via interviews with 13 geographically diverse US hospitals during an ongoing prospective, multi-center, observational study of IV PCA for acute postoperative pain management among subjects undergoing total knee or hip replacement or abdominal hysterectomy. An interim analysis was performed on data from 13 of 32 planned hospitals. RESULTS: Average IV PCA pump inventory